CardiOptix is pioneering a new era in cardiac care with breakthrough monitoring technology that detects heart failure progression before symptoms appear, enabling proactive intervention and dramatically improving patient outcomes.
Our breakthrough technology delivers unprecedented advantages across clinical, technical, and economic dimensions.
Outperforms all existing solutions in specificity, sensitivity, and predictive accuracy.
Advanced machine learning algorithms that increase diagnostic value exponentially.
Strong intellectual property portfolio with multiple granted patents and applications.
Current technologies fail to provide early enough detection, leading to preventable hospitalizations, unnecessary costs, and patient suffering.
.jpg)
Heart failure affects more people than all cancers combined, with 64 million patients worldwide today and projected to reach 75 million by 2030. Despite advances in cardiac care, detection remains dangerously delayed.
Current implantable devices provide only 10-20 days of warning after clinical symptoms begin, leaving patients vulnerable to sudden hospitalization and life-threatening complications.
Within 30 days post-discharge, costing healthcare systems billions annually
Current ICDs misclassify events, delivering unnecessary and traumatic shocks
In the U.S. healthcare system alone due to late detection and readmissions
Located within the world's largest medical complex, CardiOptix benefits from the Texas Medical Center Innovation ecosystem.
TMC Innovation is shaping the future of health care by uniting promising innovators with the best minds in science and medicine at the member institutions of the Texas Medical Center.
Our mission is to increase the quality and quantity of healthcare startup density in Houston. Texas Medical Center Innovation forms, fosters, recruits, and funds healthcare companies from around the world that are writing the future of healthcare.
Forms, fosters, recruits, and funds healthcare companies worldwide
Works with TMC members, global advisors, and corporate partners
Rigorous evaluation of companies progressing toward clinical milestones
Access to advisors, programs, and co-working spaces worldwide
Through our partnership with TMC Innovation, CardiOptix gains access to world-renowned cardiac specialists, clinical trial opportunities, regulatory expertise, and collaborative research networks that accelerate our development and validation processes.
.jpg)
.jpg)
.jpg)
Our team combines decades of experience in cardiology, medical device innovation, and business execution.
World-renowned cardiac specialists guiding our clinical development and validation.
CardiOptix outperforms all existing solutions across critical metrics for heart failure management.
Eliminates false positives and unnecessary interventions through precise hemodynamic monitoring.
Detects heart failure during asymptomatic phase, providing 3x earlier warning than competitors.
Mitigates rhythm misclassification, preventing life-threatening inappropriate shocks from ICDs.
Request our complete investor package or schedule a meeting with our executive team.
Interested in learning more about CardiOptix investment opportunities? Fill out the form and our team will provide you with detailed materials within 24 hours.
Xavier Staggs, CEO
xstaggs@cardioptix.com
contact@cardioptix.com
Full data room access available after NDA execution
All investor materials are confidential and intended for qualified investors only. Please contact us to execute an NDA for full access to our data room including financial projections, clinical study results, and intellectual property portfolio.
CardiOptix represents a breakthrough in cardiac care with the potential to save lives, reduce healthcare costs by billions, and capture significant market share. Join us in revolutionizing heart failure management.
